Keystone Financial Planning Inc. grew its stake in Amgen, Inc. (NASDAQ:AMGN) by 21.2% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,433 shares of the medical research company’s stock after purchasing an additional 425 shares during the quarter. Keystone Financial Planning Inc.’s holdings in Amgen were worth $399,000 at the end of the most recent reporting period.
Several other hedge funds also recently bought and sold shares of the company. Alpha Omega Wealth Management LLC lifted its holdings in Amgen by 19.0% during the first quarter. Alpha Omega Wealth Management LLC now owns 625 shares of the medical research company’s stock worth $103,000 after acquiring an additional 100 shares during the period. Jackson Grant Investment Advisers Inc. lifted its holdings in Amgen by 0.6% during the first quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock worth $104,000 after acquiring an additional 4 shares during the period. Nelson Roberts Investment Advisors LLC bought a new stake in Amgen during the first quarter worth $121,000. Signature Estate & Investment Advisors LLC lifted its holdings in Amgen by 13.6% during the first quarter. Signature Estate & Investment Advisors LLC now owns 794 shares of the medical research company’s stock worth $130,000 after acquiring an additional 95 shares during the period. Finally, Cribstone Capital Management LLC lifted its holdings in Amgen by 2.3% during the first quarter. Cribstone Capital Management LLC now owns 1,113 shares of the medical research company’s stock worth $182,000 after acquiring an additional 25 shares during the period. Institutional investors own 78.14% of the company’s stock.
Shares of Amgen, Inc. (NASDAQ:AMGN) traded down 1.04% during midday trading on Friday, reaching $187.47. The company’s stock had a trading volume of 5,348,992 shares. The company’s 50-day moving average price is $175.31 and its 200-day moving average price is $169.32. Amgen, Inc. has a 12 month low of $133.64 and a 12 month high of $191.10. The company has a market cap of $136.79 billion, a PE ratio of 17.08 and a beta of 1.35.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.11 by $0.16. The firm had revenue of $5.81 billion during the quarter, compared to analyst estimates of $5.67 billion. Amgen had a return on equity of 27.67% and a net margin of 37.02%. The business’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same quarter last year, the business posted $2.84 earnings per share. On average, equities analysts anticipate that Amgen, Inc. will post $12.57 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Friday, September 8th. Stockholders of record on Thursday, August 17th were given a dividend of $1.15 per share. The ex-dividend date was Tuesday, August 15th. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.45%. Amgen’s payout ratio is 41.93%.
A number of analysts recently commented on the company. Royal Bank Of Canada assumed coverage on Amgen in a report on Thursday. They set a “sector perform” rating and a $192.00 price target on the stock. Oppenheimer Holdings, Inc. reiterated a “buy” rating and set a $203.00 price target on shares of Amgen in a report on Thursday, September 7th. Cann reiterated a “buy” rating on shares of Amgen in a report on Monday, August 28th. Mizuho restated a “buy” rating and issued a $183.00 target price (down from $195.00) on shares of Amgen in a research note on Monday, August 21st. Finally, BidaskClub lowered Amgen from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. One research analyst has rated the stock with a sell rating, twelve have given a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $186.14.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with our FREE daily email newsletter.